Higher ANA Titers Linked to Increased Risks of Infertility and Miscarriage – Fertility Plus
Fertility Plus shared a post on LinkedIn:
“ANA in IVF
Recent research by Yoshihara et al. (2025) offers key insights into anti-nuclear antibodies (ANA) in reproductive health. They determined that low-titer ANA (≤1:160) does not significantly impact live birth rates, suggesting a threshold where these antibodies may become clinically relevant. Conversely, higher ANA titers have previously been linked to increased risks of infertility and miscarriage.
This study emphasizes the importance of monitoring ANA levels in pregnancy planning and highlights the need for further research into how these antibodies influence reproductive outcomes. Understanding these thresholds can empower couples during their fertility journeys.
Association between antinuclear antibodies and pregnancy prognosis in recurrent pregnancy loss patients Open Access
H Yoshihara, S Goto, Tamao Kitaori, M Sugiura-Ogasawara
Human Reproduction, Volume 40, Issue 2, February 2025, Pages 236–243.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Aug 3, 2026, 14:19Asmaa Khaled: The Success of IVF is Not Determined By the Number of Eggs Retrieved Alone…
-
Aug 3, 2026, 14:03Clare Mansfield: Sometimes the Path to Parenthood Changes, but the Dream Doesn’t Have To
-
Aug 3, 2026, 13:45Undiga Emuekpere: Basic Fertility Health Awareness Could Change Outcomes
-
Aug 3, 2026, 13:31Priyadatt Patel: A Quiet Inefficiency in How We Approach Infertility Deserves More Attention
-
Aug 3, 2026, 13:21Purabi Gunjal: Most Women Start Thinking about Fertility Too Late…
-
Aug 3, 2026, 13:10Juhee Jain: Empowering Women with the Right Information to Make Informed Decisions
-
Aug 3, 2026, 12:57Ashley Evans: Sometimes, the Thing that Got Me Through Fertility Treatment Wasn’t Positivity…
-
Aug 3, 2026, 12:42Devyanshi Dixit: Why Do the Best Healthcare Professionals Never Stop Learning?
-
Aug 3, 2026, 12:30Bringing Together the Brightest Minds in Reproductive Medicine for 3 Days at MEFS 2026
